Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

33.87USD
16 Feb 2018
Change (% chg)

$0.91 (+2.76%)
Prev Close
$32.96
Open
$33.15
Day's High
$35.17
Day's Low
$33.07
Volume
145,175
Avg. Vol
142,936
52-wk High
$41.24
52-wk Low
$16.71

Latest Key Developments (Source: Significant Developments)

Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​
Thursday, 11 Jan 2018 05:12pm EST 

Jan 11 (Reuters) - La Jolla Pharmaceutical Co ::BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​.  Full Article

La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018
Friday, 29 Dec 2017 04:40pm EST 

Dec 29 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING.  Full Article

La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure
Thursday, 21 Dec 2017 06:17pm EST 

Dec 21 (Reuters) - La Jolla Pharmaceutical Co ::U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE.U.S. FDA SAYS GRANTED THE APPROVAL OF GIAPREZA TO LA JOLLA PHARMACEUTICAL COMPANY.U.S. FDA - APPROVES GIAPREZA (ANGIOTENSIN II) INJECTION FOR INTRAVENOUS INFUSION TO INCREASE BLOOD PRESSURE IN ADULTS WITH SEPTIC/OTHER DISTRIBUTIVE SHOCK.  Full Article

La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401
Monday, 18 Dec 2017 09:00am EST 

Dec 18 (Reuters) - La Jolla Pharmaceutical Co ::INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC‑401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS.  Full Article

La Jolla Pharma files for mixed shelf of up to $150 mln ‍​
Friday, 27 Oct 2017 05:42pm EDT 

Oct 27 (Reuters) - La Jolla Pharmaceutical Co :Files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

La Jolla reports Q3 loss $1.19/shr
Thursday, 26 Oct 2017 05:10pm EDT 

Oct 26 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Q3 loss per share $1.19.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.La Jolla Pharmaceutical-‍as of Sept 30, 2017, co had $120.8 million in cash,cash equivalents, versus $65.7 million of cash and cash equivalents at Dec 31, 2016​.  Full Article

Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical
Tuesday, 10 Oct 2017 12:35pm EDT 

Oct 10 (Reuters) - La Jolla Pharmaceutical Co ::Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍.  Full Article

FDA accepts La Jolla Pharmaceutical's NDA for LJPC-501
Monday, 28 Aug 2017 09:00am EDT 

Aug 28 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces U.S. Fda acceptance of new drug application for LJPC-501.La Jolla Pharmaceutical Co- ‍user fee goal date under prescription drug user fee act is February 28, 2018 for LJPC-501​.La Jolla Pharmaceutical-‍in letter to co, FDA stated it does not currently plan to hold advisory committee meeting to discuss application for LJPC-501​.  Full Article

La Jolla Pharma ‍announces launch of expanded access program for LJPC-501​
Tuesday, 8 Aug 2017 09:00am EDT 

Aug 8 (Reuters) - La Jolla Pharmaceutical Co ::La Jolla Pharmaceutical Co - ‍announces launch of expanded access program for LJPC-501​.  Full Article

La Jolla quarterly loss per share $1.21
Thursday, 27 Jul 2017 04:00pm EDT 

July 27 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2017 and recent corporate progress.Quarterly loss per share $1.21.La Jolla Pharmaceutical Co - as of June 30, 2017, company had $141.3 million in cash and cash equivalents.  Full Article

BRIEF-La Jolla Pharmaceutical Says Established Wholesale Acquisition Cost of Single-Dose Vial Of Giapreza At $1,500/ Vial

* LA JOLLA PHARMACEUTICAL CO - ESTABLISHED WHOLESALE ACQUISITION COST OF $1,500 PER VIAL FOR A 1 ML, SINGLE-DOSE, 2.5 MG/ML VIAL OF GIAPREZA Source text: (http://bit.ly/2nm3hfv) Further company coverage: